文献速递肝病

卡维地洛在无高危食管静脉曲张的肝硬化新发非复杂性腹水患者中的疗效与安全性(CARVE-AS试验)

Efficacy and Safety of Carvedilol in Cirrhosis Patients With New-Onset Uncomplicated Ascites Without High-Risk Esophageal Varices (CARVE-AS Trial).
PubMed 文献 · Am J Gastroenterol · 2025-07-21

这项开放标签随机对照试验将104例无或低危食管静脉曲张的肝硬化新发非复杂性腹水患者随机分为卡维地洛组(A组,n=52)和无卡维地洛组(B组,n=52),均接受标准治疗。1年时A组腹水相关并发症发生率低于B组(38.5% vs 67.3%,P=0.03),主要与急性肾损伤发生率降低有关(34.6% vs 63.4%,P=0.003)。卡维地洛与1年死亡率降低相关(9.1% vs 24.2%,P=0.05),无治疗相关严重不良事件。

要点

  • 卡维地洛组1年腹水相关并发症发生率为38.5%,低于对照组的67.3%(P=0.03)。
  • 卡维地洛组急性肾损伤发生率为34.6%,低于对照组的63.4%(P=0.003)。
  • 卡维地洛组1年死亡率为9.1%,低于对照组的24.2%(P=0.05),无治疗相关严重不良事件。

核心结论

  • 在无高危食管静脉曲张的肝硬化新发非复杂性腹水患者中,卡维地洛安全,可预防进一步的腹水相关并发症,减少大量腹腔穿刺需求并改善生存。

研究设计与样本

  • 开放标签随机对照试验,纳入104例无或低危食管静脉曲张的肝硬化新发非复杂性腹水患者,随机分为卡维地洛组(A组,n=52)和无卡维地洛组(B组,n=52),均接受标准治疗。

主要发现

  • A组与B组相比,复杂性腹水发生率更低(38.5% vs 67.3%;P=0.03),主要与急性肾损伤发生率降低有关(34.6% vs 63.4%,P=0.003),以及难治性腹水和自发性细菌性腹膜炎减少。
  • A组HVPG从14.89±2.8 mmHg降至11.86±1.9 mmHg(P<0.05),静脉曲张分级进展更少(21.8% vs 53.1%,P=0.009)。
  • A组腹水消退率更高(61.5% vs 31.8%,P=0.01),大量腹腔穿刺次数更少(26.9% vs 57.6%;P=0.01)。
  • 1年时B组Child-Turcotte-Pugh评分高于A组(9.31±1.43 vs 8.17±1.7,P=0.001)。
  • 卡维地洛使用与1年死亡率降低相关(9.1% vs 24.2%,P=0.05),无患者发生治疗相关严重不良事件。

关键数值与推荐

  • 复合主要结局为1年内任何腹水相关并发症发生率,包括自发性细菌性腹膜炎、肝肾综合征急性肾损伤、难治性腹水或重度低钠血症。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Carvedilol is effective in the prevention of bleeding in patients with cirrhosis and high-risk varices. Although it reduces drivers of clinical decompensation (portal pressure, systemic inflammation, and bacterial translocation), the data on its use for prevention of ascites-related complications are limited. METHODS: In this open-label randomized control tria, patients having uncomplicated new-onset ascites with no or low-risk esophageal varices were randomized (n = 104) to receive carvedilol (group A, n = 52) or no carvedilol (group B, n = 52) in addition to standard treatment. The composite primary outcome was incidence of any ascites-related complications, namely, spontaneous bacterial peritonitis, hepatorenal syndrome acute kidney injury, refractory ascites, or severe hyponatremia at 1 year. The secondary outcomes included need for paracentesis, change in hepatic venous pressure gradient, Child-Turcotte-Pugh, and Model for End-Stage Liver Disease score and mortality at 1 year. RESULTS: The baseline characteristics were comparable between the groups, with metabolic dysfunction-associated steatotic liver disease as the commonest etiology (overall 41.3%) followed by alcohol-associated liver disease (21.2%). Patients in group A compared with group B had lower incidence of complicated ascites (38.5% vs 67.3%; P = 0.03), mainly related to reduced incidence of acute kidney injury (AKI) (34.6% vs 63.4%, P = 0.003), refractory ascites, and spontaneous bacterial peritonitis along with a significant reduction in HVPG (14.89 ± 2.8 to 11.86 ± 1.9 mm Hg [ P < 0.05]) and lesser progression in variceal grade (21.8% vs 53.1%, P = 0.009). Patients in group A than B demonstrated better ascites resolution (61.5% vs 31.8%, P = 0.01) and fewer large volume paracentesis sessions (26.9% vs 57.6%; P = 0.01). At 1 year, patients in group B had higher Child-Turcotte-Pugh scores (9.31 ± 1.43 vs 8.17 ± 1.7, P = 0.001). Use of carvedilol was associated with lower 1 year mortality (9.1% vs 24.2%, P = 0.05). No patient had treatment-related severe adverse events. DISCUSSION: Administration of carvedilol in patients with cirrhosis with new-onset uncomplicated ascites without high-risk varices is safe and prevents further ascites-related complications, with reduced need for large volume paracentesis and improved survival.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Khajuria R, Jindal A, Sharma MK, et al. Efficacy and Safety of Carvedilol in Cirrhosis Patients With New-Onset Uncomplicated Ascites Without High-Risk Esophageal Varices (CARVE-AS Trial). Am J Gastroenterol. 2025. PMID: 40689908. doi:10.14309/ajg.0000000000003650

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。